---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-018038"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2022-06-29T23:59:59+00:00"
generated_at: "2026-06-24T22:15:47.360178+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics updates clinical milestones; plans US re-submission and Phase I/IIa trial in Germany by Q3 2022

## Summary
- Company completing requirements to answer regulatory questions and begin US re-submission process.
- Submitting filing in Europe to commence Phase I/IIa trial at a major CRO site in Germany anticipated to start Q3 2022.
- Further updates to clinical development schedule to be provided as it becomes clearer.

## SEC filing metadata
- accession: 0001493152-22-018038
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2022-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315222018038/0001493152-22-018038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315222018038/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-018038
- JSON: https://secwatch.observer/filing/0001493152-22-018038.json
- Plain text: https://secwatch.observer/filing/0001493152-22-018038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.